1.
Cureus
; 15(3): e35874, 2023 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37033542
RESUMO
Gemcitabine-induced hemolytic uremic syndrome is an often-missed condition. We present a case outlining the successful management of a patient with metastatic cholangiocarcinoma treated with gemcitabine who subsequently developed hemolytic uremic syndrome. Early recognition and stopping gemcitabine are essential in this patient population. Complement inhibitors have been used, and our patient improved on eculizumab therapy.